<DOC>
	<DOCNO>NCT02492750</DOCNO>
	<brief_summary>This partially randomized phase I/II trial study side effect best dose anakinra give together lenalidomide dexamethasone treat patient early stage multiple myeloma . Biological therapy , lenalidomide anakinra , may stimulate suppress immune system different way stop cancer cell grow . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . It yet know whether lenalidomide dexamethasone effective without anakinra treat patient multiple myeloma .</brief_summary>
	<brief_title>Lenalidomide Dexamethasone With Without Anakinra Treating Patients With Early Stage Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) /maximum allowable dose ( MAD ) anakinra combine lenalidomide dexamethasone . ( Phase I ) II . To compare time progression standard treatment arm ( lenalidomide/dexamethasone ) experimental arm ( lenalidomide/dexamethasone + anakinra ) . ( Phase II ) SECONDARY OBJECTIVES : I . To compare response rate standard treatment arm ( lenalidomide/dexamethasone ) experimental arm ( lenalidomide/dexamethasone + anakinra ) . II . To compare toxicity standard treatment arm ( lenalidomide/dexamethasone ) experimental arm ( lenalidomide/dexamethasone + anakinra ) . III . To compare overall survival standard treatment arm ( lenalidomide/dexamethasone ) experimental arm ( lenalidomide/dexamethasone + anakinra ) . OUTLINE : This phase I , dose-escalation study anakinra follow phase II study . PHASE I : Patients receive lenalidomide orally ( PO ) day 1-21 dexamethasone PO day 1 , 8 , 15 , 22 . Patients also receive anakinra subcutaneously ( SC ) day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PHASE II : Patients randomize 1 2 treatment arm . ARM A : Patients receive lenalidomide PO day 1-21 dexamethasone PO day 1 , 8 , 15 , 22 . Patients also receive anakinra SC day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM B : Patients receive lenalidomide dexamethasone Arm A . Patients also receive placebo SC day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Absolute neutrophil count ( ANC ) &gt; = 1700/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 8.0 g/dL Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 3 x upper limit normal ( ULN ) Creatinine clearance &gt; = 30 mL/min ( determine CockroftGault equation ) Diagnosis multiple myeloma accord International Myeloma Working Group criteria one following : Smoldering multiple myeloma ( SMM ) Indolent multiple myeloma ( IMM ) Newly diagnose multiple myeloma ( MM ) Note : patient lytic disease anemia eligible High risk disease define follow : &gt; = 10 % bone marrow plasma cell AND Abnormal serum free light chain ( FLC ) ratio ( &lt; 0.26 &gt; 1.65 ) serum FLC assay AND Monotypic plasma cell Sphase &gt; = 1 % Measurable level Mprotein &gt; 1 g/dL serum protein electrophoresis &gt; 200 mg Mprotein 24 hour urine protein electrophoresis Negative tuberculosis ( TB ) testing ( Quantiferon TB blood test skin test ) = &lt; 7 day prior registration Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Provide sign informed consent Negative ( serum urine ) pregnancy test do = &lt; 7 day prior registration , woman childbearing potential ; NOTE : second pregnancy test must perform within 24 hour prior start lenalidomide ; subject may receive lenalidomide study doctor verify result pregnancy test negative Willing return enrol institution followup ( active monitoring phase study ) Willing able comply requirement Revlimid Risk Evaluation Mitigation Strategy ( REMS ) program Females childbearing potential must willing adhere schedule pregnancy test require Revlimid REMS program Prior treatment agent may affect Mprotein = &lt; 30 day prior registration Acute/chronic infection , open wound , active infection require intravenous antibiotic therapy = &lt; 12 week prior registration Other active malignancy ( = &lt; 3 year ) prior registration ; exception : basal cell skin cancer carcinomainsitu cervix lowrisk prostate cancer curative therapy Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception New York Heart Association ( NYHA ) class 3 4 congestive heart failure ( CHF ) symptoms Other concurrent chemotherapy , radiotherapy , ancillary therapy consider investigational ; NOTE : bisphosphonates allow protocol treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>